Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14244066 | 0.81 | MEN1 (0.53) | ALDH1A1SMN1; SMN2MAPTUSP2ALOX15 | |
| SCHEMBL2463445 | 0.80 | APP (0.56) | ALDH1A1APPMAPTACHENPSR1 | |
| SCHEMBL28526402 | 0.74 | APP (0.55) | ALDH1A1APPUSP2ALOX15MAPK1 | |
| SCHEMBL14299528 | 0.74 | APP (0.46) | ALDH1A1APPSMN1; SMN2ACHEUSP2 | |
| SCHEMBL28134373 | 0.73 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTL3MBTL1GAA | |
| SCHEMBL13098121 | 0.68 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MAPTL3MBTL1CYP2C9 | |
| E1501 SCHEMBL901210 | 0.67 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MAPTL3MBTL1MAPK1 | |
| E1501 SCHEMBL14031569 | 0.67 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MAPTL3MBTL1MAPK1 | |
| E1501 SCHEMBL43745 | 0.67 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MAPTL3MBTL1MAPK1 | |
| E1501 SCHEMBL28201296 | 0.67 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MAPTL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556081-B1 | A CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | INST CHEMII BIOORGANICZNEJ PAN (PL) | 2021-06-16 | — | — | EP | disclosed |
| US-9040490-B2 | Cytosine analogue, a method of preparation of a cytosine analogue, a DNA methyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2015-05-26 | — | — | US | disclosed |
| US-9040490-B2 | Cytosine analogue, a method of preparation of a cytosine analogue, a DNA methyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2015-05-26 | — | — | US | disclosed |
| US-20120322755-A1 | CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322755-A1 | CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | DNMT1, DIMT1, TPMT | ALDH1A1 792/4885APP 3910/4885SMN1; SMN2 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.